Christopher Leo, PhD
Partner, Managing Director
Christopher Leo is a founding member of Back Bay Life Science Advisors. His focus areas include corporate growth, business unit, product/market strategy development, and due diligence support for clients ranging from emerging biotech through specialty pharma and large biopharma/medtech/tools companies.
Dr. Leo has 20 years of strategic advisory experience across markets and therapeutic areas, with a particular focus on rare diseases, women’s health/fertility, neurology, and autoimmune diseases.
Dr. Leo joined Back Bay Life Science Advisors from Genzyme, where he led strategic & competitive planning projects for the company’s rare genetic disease and biosurgery business units. Before Genzyme, he was a Director with Leerink Swann’s Strategic Advisory group and a Principal in Wood Mackenzie’s Life Science consulting practice. Before transitioning to strategy consulting, Dr. Leo was Director of the Belfer Cancer Genomics Center at the Dana Farber Cancer Institute.
Dr. Leo completed his doctorate in Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School and holds an undergraduate degree in Biology, cum laude, from The College of the Holy Cross.
Select industry insights by Dr. Leo:
Medicare Prescription Drug Changes in the Inflation Reduction Act
STAT: Early-Stage Price Setting
Nature BioPharma Dealmakers: From Drug Target Inhibition to Degradation: a TACtical Strategy